



## **Annelie Skafte Persson appointed new CEO of Cellectricon**

**Gothenburg, Sweden, 13 November 2009: Cellectricon, a leading provider of screening solutions for drug discovery, announced today that Annelie Skafte Persson has accepted the position as Chief Executive Officer. The appointment is effective immediately in conjunction with Jonas Ohlsson's resignation as the company's Chief Executive Officer.**

Annelie Skafte Persson has served as CFO at Cellectricon since March 2008. Mrs. Skafte Persson has a solid background with more than 20 years of experience from finance and management roles, for example as CFO within the medical device business and CEO for company developing and providing air pollution control equipment.

Cellectricon's Chairman **Lars-Eric Utterman** said: "Cellectricon is a highly innovative company providing groundbreaking products to the pharmaceutical and biotechnology industries. I am very pleased to see that Annelie Skafte Persson has accepted this position. It will allow us to ensure and continue a successful development of the Company without disruption, as Jonas Ohlsson chose to pursue other opportunities."

**Annelie Skafte Persson** said: "I am looking forward to participate in the further development of the company, together with my highly competent staff, and to successfully launch two high throughput screening systems developed in close collaboration with the pharmaceutical industry".

### **About Cellectricon**

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2008-2009 the company is launching two pioneering high throughput screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in preclinical pharmaceutical development, the Cellaxess®HT System enables high throughput transfection for genomic screening and the Dynaflow®HT System greatly advances ion channel drug discovery.

### **Contact Details:**

Annelie Skafte Persson, CEO

E-mail: [annelie.skafte.persson@cellectricon.com](mailto:annelie.skafte.persson@cellectricon.com)

Susanne Fagerlund, VP Marketing & Communications

E-mail: [susanne.fagerlund@cellectricon.com](mailto:susanne.fagerlund@cellectricon.com)